An Economic Model of 2-Hour Post-Dose Ciclosporin Monitoring in Renal Transplantation Paul A. KeownBryce KiberdZoltan Kalo Original Research Article 22 September 2012 Pages: 621 - 632
From Randomised Clinical Trials to Clinical Practice Samuel LimatMarie-Christine Woronoff-LemsiYacine Merrouche Original Research Article 22 September 2012 Pages: 633 - 641
Economic Evaluation of Etoricoxib versus Non-Selective NSAIDs in the Treatment of Osteoarthritis and Rheumatoid Arthritis Patients in the UK Andrew MooreCeri PhillipsSimone Crespi Original Research Article 22 September 2012 Pages: 643 - 660
Economic Assessment of the Secondary Prevention of Ischaemic Stroke with Dipyridamole plus Aspirin (Aggrenox®/Asasantin®) in France Jean-Pierre MarissalBernard Selke Original Research Article 22 September 2012 Pages: 661 - 670
Warfarin in the Secondary Prevention of Thromboembolism in Atrial Fibrillation Nicole MittmannPaul I. OhWilliam R. Bartle Original Research Article 22 September 2012 Pages: 671 - 683
On Cost Effectiveness and Sample Size in Clinical Trials Augustinus A. M. HartMarcel G. W. Dijkgraaf Correspondence 22 September 2012 Pages: 685 - 688
On Cost Effectiveness and Sample Size in Clinical Trials. The Author’s Reply Martin E. Backhouse Correspondence 22 September 2012 Pages: 688 - 689
